Providence Saint Johns Cancer Institute

Santa Monica, California 90404

2 studies enrolling now · 8 studies all time

What they study most

Astrocytoma, Bladder Cancer, Breast Cancer, Glioblastoma Multiforme, Glioma, H3 K27M, High-grade Glioma, Intermediate Risk Non-Muscle Invasive Bladder Cancer, Low-grade Upper Tract Urothelial Carcinoma, Melanoma, Merkel Cell Carcinoma, Unspecified, Metastatic Hormone-sensitive Prostate Cancer

Studies at this site

• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis — Recruiting now
• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. — Running, not enrolling
• The OPBC-07/microNAC Study — Running, not enrolling
• Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma — Running, not enrolling
• Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies — Status unconfirmed